BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30982572)

  • 1. The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy.
    Kozman MA; Fisher OM; Valle SJ; Alzahrani N; Liauw W; Morris DL
    Am J Surg; 2020 Jan; 219(1):58-64. PubMed ID: 30982572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
    J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volume-Time Index Is Not an Indicator of Outcome for Patients Undergoing CRS/HIPEC for Treatment of High-Grade Appendiceal Carcinomatosis.
    Dotta DM; Lansom JD; Fisher OM; Fracs NAA; Liauw W; Morris DL
    Anticancer Res; 2019 Dec; 39(12):6813-6817. PubMed ID: 31810947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
    Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
    Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative packed red blood cell transfusion (iPRBT) and PCI-normalised iPRBT rates (iPRBT/PCI ratio) negatively affect short- and long-term outcomes of patients undergoing cytoreductive surgery and intraperitoneal chemotherapy - An analysis of 880 patients.
    Fisher OM; Alzahrani NA; Kozman MA; Valle SJ; Liauw W; Morris DL
    Eur J Surg Oncol; 2019 Dec; 45(12):2412-2423. PubMed ID: 31444027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?
    Baratti D; Kusamura S; Iusco D; Cotsoglou C; Guaglio M; Battaglia L; Virzì S; Mazzaferro V; Deraco M
    Dis Colon Rectum; 2018 Sep; 61(9):1026-1034. PubMed ID: 30086051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.
    Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL;
    J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
    Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate.
    Cashin PH; Dranichnikov F; Mahteme H
    J Surg Oncol; 2014 Aug; 110(2):203-6. PubMed ID: 24846340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
    Gelli M; Huguenin JFL; de Baere T; Benhaim L; Mariani A; Boige V; Malka D; Sourouille I; Ducreux M; Elias D; Goéré D
    Eur J Cancer; 2018 Sep; 100():94-103. PubMed ID: 30014885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
    Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis.
    Bin Traiki TA; Fisher OM; Valle SJ; Parikh RN; Kozman MA; Glenn D; Power M; Liauw W; Alzahrani NA; Morris DL
    Eur J Surg Oncol; 2017 Oct; 43(10):1939-1948. PubMed ID: 28888800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis.
    Ng JL; Ong WS; Chia CS; Tan GH; Soo KC; Teo MC
    Int J Surg Oncol; 2016; 2016():2495131. PubMed ID: 27006828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.
    Goéré D; Souadka A; Faron M; Cloutier AS; Viana B; Honoré C; Dumont F; Elias D
    Ann Surg Oncol; 2015 Sep; 22(9):2958-64. PubMed ID: 25631064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.